Control of Hepatitis B Virus with Imdusiran, a Small Interfering RNA Therapeutic
- 22 September 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (10) , 3640-3649
Abstract
Chronic hepatitis B is a global health concern with a high risk of end-stage liver disease. Current standard-of-care agents have low cure rates, and new therapies are needed. Small interfering RNAs (siRNAs) that target viral RNAs fulfill a gap not addressed by standard-of-care agents and may contribute to a functional cure. Here, we describe the preclinical characterization of imdusiran (AB-729), a novel, pan-genotypic siRNA therapeutic that effectively reduces HBsAg, viral antigens, and viral replication in chronic hepatitis B patients and is currently in Phase 2 clinical studies. In hepatitis B virus (HBV) cell-based systems, imdusiran possessed pan-genotypic nanomolar potency and retained activity against HBV target site polymorphisms. Imdusiran was active against nucleos(t)ide analogue- and capsid assembly modulator-resistant HBV isolates, and combination with standard-of-care agents was additive. In an HBV adeno-associated virus mouse model, HBsAg was reduced up to 3.7 log10 after a single imdusiran dose, with sustained suppression for 10 weeks. Imdusiran did not intrinsically stimulate cytokine release in healthy donor human whole blood, supportive of its mechanism of action as a direct acting RNA interference antiviral. Taken together, these data support imdusiran in combination treatment approaches toward chronic hepatitis B functional cure.Keywords
This publication has 27 references indexed in Scilit:
- Therapeutic siRNA: State-of-the-Art and Future PerspectivesBioDrugs, 2022
- Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core proteinAntiviral Research, 2022
- Intramolecular recombination enables the formation of hepatitis B virus (HBV) cccDNA in mice after HBV genome transfer using recombinant AAV vectorsAntiviral Research, 2021
- Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vectorAntiviral Research, 2017
- Hepatitis B virus antigens impair NK cell functionInternational Immunopharmacology, 2016
- Erratum to: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 updateHepatology International, 2012
- A rapid two-step method for isolation of functional primary mouse hepatocytes: cell characterization and asialoglycoprotein receptor based assay developmentCytotechnology, 2011
- The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinomaJournal of Gastroenterology, 2009
- Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA LevelJAMA, 2006
- A three-dimensional model to analyze drug-drug interactionsAntiviral Research, 1990